# US 2026/0060974 A1 · Therapeutic tyrosine kinase inhibitors for multiple sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060974 A1
- Document ID: US20260060974A1
- Status: Published application
- Kind: A1
- Application number: 19/313,165
- Filed: 2025-08-28
- Published: 2026-03-05
- Earliest claimed: 2024-08-30
- Assignees: Principia Biopharma Inc.
- Applicants: Principia Biopharma Inc.
- Inventors: Deborah Dukovic; Sana Syed; Timothy J. Turner
- Web page: https://patentgrep.com/patent/US20260060974A1

## CPC

- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of patients with multiple sclerosis (MS).

## Claims

### Claim 1

A method of treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein at least one outcome chosen from the following occurs:
(a) the risk of confirmed disability progression (CDP) is reduced;
(b) the total number of new and/or enlarging T2-hyperintense lesions as detected by MRI, defined as the sum of the individual number of new and/or enlarging T2 lesions, are reduced;
(c) the risk of sustained 20% increase in the timed 25-foot walk (T25-FW) test confirmed over at least 3 months is reduced; and
(d) the chance of confirmed disability improvement (CDI) is improved.

### Claim 2

A method of treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein the risk of confirmed disability progression (CDP) is reduced.

### Claim 3 (depends on 2)

The method of claim 2, wherein the CDP is measured over at least three months, such as at least six months.

### Claim 4 (depends on 2, 3)

The method of claim 2 or 3, wherein the confirmed disability progression (CDP) comprises:
(a) increasing at least 1.0 point from a baseline expanded disability status scale score (EDSS) when the baseline score is less than or equal to 5.0; or
(b) increasing at least 0.5 points when the baseline EDSS score is greater than 5.0.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 6

A method of reducing the risk of confirmed disability progression (CDP) in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the CDP is measured over at least three months, such as at least six months.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein confirmed disability progression (CDP) comprises:
(a) increasing at least 1.0 point from a baseline expanded disability status scale score (EDSS) when the baseline score is less than or equal to 5.0; or
(b) increasing at least 0.5 points when the baseline EDSS score is greater than 5.0.

### Claim 9 (depends on 6, 7, 8)

The method of any one of claims 6-8, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 10 (depends on 6, 7, 8, 9)

The method of any one of claims 6-9, wherein the risk reduction is relative to placebo.

### Claim 11

A method of reducing the total number of new and/or enlarging T2-hyperintense lesions as detected by MRI, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein reducing comprises reducing the annualized rate of new and/or enlarging T2-hyperintense lesions.

### Claim 13 (depends on 11, 12)

The method of claim 11 or 12, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 14 (depends on 12)

The method of claim 12, wherein the annualized rate is reduced relative to placebo.

### Claim 15

A method of reducing the risk of sustained 20% increase in the timed 25-foot walk (T25-FW) test confirmed over at least 3 months, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the risk reduction is relative to placebo.

### Claim 18

A method of reducing the risk of sustained 20% increase in the 9-hole peg test (9-HPT) confirmed over at least 3 months, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 20 (depends on 18, 19)

The method of claim 18 or 19, wherein the risk reduction is relative to placebo.

### Claim 21

A method of improving the chance of confirmed disability improvement (CDI) in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the CDI is measured over at least three months, such as at least six months.

### Claim 23 (depends on 22)

The method of claim 22, wherein the confirmed disability improvement (CDI) comprises decreasing at least 1.0 point from a baseline expanded disability status scale score (EDSS).

### Claim 24 (depends on 22, 23)

The method of claim 22 or 23, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 25 (depends on 22, 23, 24)

The method of any one of claims 22-24, wherein the chance is improved relative to placebo.

### Claim 26

A method of improving time to onset of confirmed disability progression (CDP) in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the CDP is measured over at least three months, such as at least six months.

### Claim 28 (depends on 26, 27)

The method of claim 26 or 27, wherein the confirmed disability progression (CDP) comprises:
(a) increasing at least 1.0 point from a baseline expanded disability status scale score (EDSS) when the baseline score is less than or equal to 5.0; or
(b) increasing at least 0.5 points when the baseline EDSS score is greater than 5.0.

### Claim 29 (depends on 26, 27, 28)

The method of any one of claims 26-28, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 30

A method of improving time to onset of sustained 20% increase in the timed 25-foot walk (T25-FW) test confirmed over at least 3 months, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 30)

The method of claim 30, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 32

A method of improving time to onset of sustained 20% increase in the 9-hole peg test (9-HPT) confirmed over at least 3 months, in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 34

A method of improving time to onset of confirmed disability improvement (CDI) in a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein the time to onset of CDI is measured over at least three months, such as at least six months.

### Claim 36 (depends on 34, 35)

The method of claim 34 or 35, wherein the confirmed disability improvement (CDI) comprises decreasing at least 1.0 point from a baseline expanded disability status scale score (EDSS).

### Claim 37 (depends on 34, 35, 36)

The method of any one of claims 34-36, wherein the patient with nrSPMS has:
(a) a SPMS diagnosis with an expanded disability status scale score (EDSS) between 3.0 and 6.5;
(b) no clinical relapse in the previous 24 months; and
(c) disability accumulation in the previous 12 months.

### Claim 38 (depends on 1, 2, 3, 4, 5)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS) in the method of any one of claims 1-5.

### Claim 39 (depends on 6, 7, 8, 9, 10)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof reduces the risk of confirmed disability progression (CDP) in the method of any one of claims 6-10.

### Claim 40 (depends on 11, 12, 13, 14)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof reduces the total number of new and/or enlarging T2-hyperintense lesions as detected by MRI in the method of any one of claims 11-14.

### Claim 41 (depends on 15, 16, 17)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof reduces the risk of sustained 20% increase in the timed 25-foot walk (T25-FW) test confirmed over at least 3 months in the method of any one of claims 15-17.

### Claim 42 (depends on 18, 19, 20)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof reduces the risk of sustained 20% increase in the 9-hole peg test (9-HPT) confirmed over at least 3 months in the method of any one of claims 18-20.

### Claim 43 (depends on 21, 22, 23, 24, 25)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof improves the chance of confirmed disability improvement (CDI) in the method of any one of claims 21-25.

### Claim 44 (depends on 26, 27, 28, 29)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof improves time to onset of confirmed disability progression (CDP) in the method of any one of claims 26-29.

### Claim 45 (depends on 30, 31)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof improves time to onset of sustained 20% increase in the timed 25-foot walk (T25-FW) test confirmed over at least 3 months in the method of any one of claims 30-31.

### Claim 46 (depends on 32, 33)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof improves time to onset of sustained 20% increase in the 9-hole peg test (9-HPT) confirmed over at least 3 months in the method of any one of claims 32-33.

### Claim 47 (depends on 34, 35, 36, 37)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with non-relapsing secondary progressive multiple sclerosis (nrSPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof improves time to onset of confirmed disability improvement (CDI) in the method of any one of claims 34-37.

### Claim 48

A method of reducing the risk of confirmed disability worsening (CDW) in a patient with a relapsing form of multiple sclerosis (RMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 48)

The method of claim 48, wherein the CDW is measured over at least three months, such as at least six months.

### Claim 50 (depends on 48, 49)

The method of claim 48 or 49, wherein CDW comprises:
(a) increasing at least 1.5 point from a baseline expanded disability status scale score (EDSS) when the baseline score is 0;
(b) increasing at least 1.0 point from the baseline EDSS when the baseline score is greater than or equal to 0.5 and less than or equal to 5.5; or
(c) increasing at least 0.5 points when the baseline EDSS score is greater than 5.5.

### Claim 51 (depends on 48, 49, 50)

The method of any one of claims 48-50, wherein the patient has an RMS diagnosis with an EDSS less than or equal to 5.5 prior to initial administration of tolebrutinib, and one or more of the following:
(a) one or more documented relapses in the previous year;
(b) two or more documented relapses in the previous 2 years; and
(c) one or more Gd-enhancing lesions on an MRI scan in the previous year.

### Claim 52 (depends on 48, 49, 50, 51)

The method of any one of claims 48-51, wherein the risk reduction is relative to treatment with teriflunomide.

### Claim 53

A method of improving time to onset of confirmed disability worsening (CDW) in a patient with a relapsing form of multiple sclerosis (RMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein the CDW is measured over at least three months, such as at least six months.

### Claim 55 (depends on 53, 54)

The method of claim 53 or 54, wherein CDW comprises:
(a) increasing at least 1.5 point from a baseline expanded disability status scale score (EDSS) when the baseline score is 0;
(b) increasing at least 1.0 point from the baseline EDSS when the baseline score is greater than or equal to 0.5 and less than or equal to 5.5; or
(c) increasing at least 0.5 points when the baseline EDSS score is greater than 5.5.

### Claim 56 (depends on 53, 54, 55)

The method of any one of claims 53-55, wherein the patient has an RMS diagnosis with an EDSS less than or equal to 5.5 at the first visit, and one or more of the following:
(a) one or more documented relapses in the previous year;
(b) two or more documented relapses in the previous 2 years; and
(c) one or more Gd-enhancing lesions on an MRI scan in the previous year.

### Claim 57

A method of improving percent change in brain volume loss (BVL) as detected by brain MRI in a patient with relapsing forms of multiple sclerosis (RMS), comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 58 (depends on 57)

The method of claim 57, wherein the patient has an RMS diagnosis with an EDSS less than or equal to 5.5 at the first visit, and one or more of the following:
(a) one or more documented relapses in the previous year;
(b) two or more documented relapses in the previous 2 years; and
(c) one or more Gd-enhancing lesions on an MRI scan in the previous year.

### Claim 59 (depends on 57, 58)

The method of claim 57 or 58, wherein the percent change BVL improvement is relative to treatment with teriflunomide.

### Claim 60 (depends on 48, 49, 50, 51, 52)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with a relapsing form of multiple sclerosis (RMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof reduces the risk of confirmed disability worsening (CDW) in the method of any one of claims 48-52.

### Claim 61 (depends on 53, 54, 55, 56)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with a relapsing form of multiple sclerosis (RMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof reduces improves time to onset of confirmed disability worsening (CDW) in the method of any one of claims 53-56.

### Claim 62 (depends on 57, 58, 59)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with a relapsing form of multiple sclerosis (RMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof reduces improves percent change in brain volume loss (BVL) as detected by brain MRI in the method of any one of claims 57-59.

### Claim 63

A method of treating a patient with primary progressive multiple sclerosis (PPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein at least one outcome chosen from the following occurs:
(a) the risk of composite confirmed disability progression (cCDP) is reduced, wherein the cCDP comprises progression in at least one of confirmed disability progression (CDP), sustained 20% increase in the timed 25-foot walk (T25-FW) test, and sustained 20% increase in the 9-hole peg test (9-HPT);
(b) the risk of confirmed disability progression (CDP) is reduced;
(c) the total number of new and/or enlarging T2-hyperintense lesions as detected by MRI, defined as the sum of the individual number of new and/or enlarging T2 lesions, are reduced;
(d) the risk of sustained 20% increase in the timed 25-foot walk (T25-FW) test is reduced;
(e) the risk of sustained 20% increase in the 9-hole peg test (9-HPT) is reduced;
(f) the chance of confirmed disability improvement (CDI) is improved; and
(g) the percent change in brain volume loss (BVL) as detected by brain MRI is improved.

### Claim 64

A method of treating a patient with primary progressive multiple sclerosis (PPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein the risk of confirmed disability progression (CDP) or composite confirmed disability progression (cCDP) is reduced, wherein the cCDP comprises progression in at least one of:
(a) CDP;
(b) sustained 20% increase in the timed 25-foot walk (T25-FW) test; and
(c) sustained 20% increase in the 9-hole peg test (9-HPT).

### Claim 65 (depends on 63, 64)

The method of claim 63 or 64, wherein the CDP, cCDP, sustained 20% increase in the timed 25-foot walk (T25-FW) test, or sustained 20% increase in the 9-hole peg test (9-HPT) is measured over at least three months, such as at least six months.

### Claim 66 (depends on 63, 64, 65)

The method of claim any one of claims 63-65, wherein the CDP comprises:
(a) increasing at least 1.0 point from a baseline expanded disability status scale score (EDSS) when the baseline score is less than or equal to 5.5; or
(b) increasing at least 0.5 points when the baseline EDSS score is greater than 5.5.

### Claim 67 (depends on 63, 64, 65, 66)

The method of any one of claims 63-66, wherein the patient with PPMS has:
(a) a PPMS diagnosis with an expanded disability status scale score (EDSS) between 2.0 and 6.5; and
(b) a cerebrospinal fluid (CSF) analysis that is positive for isoelectric focusing evidence of oligoclonal bands or elevated IgG index.

### Claim 68

A method of reducing the risk of confirmed disability progression (CDP) or composite confirmed disability progression (cCDP) in a patient with primary progressive multiple sclerosis (PPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein the cCDP comprises progression in at least one of:
(a) CDP;
(b) sustained 20% increase in the timed 25-foot walk (T25-FW) test; and
(c) sustained 20% increase in the 9-hole peg test (9-HPT).

### Claim 69 (depends on 68)

The method of claim 68, wherein the CDP or cCDP is measured over at least three months, such as at least six months.

### Claim 70 (depends on 68, 69)

The method of claim 68 or 69, wherein confirmed disability progression (CDP) comprises:
(a) increasing at least 1.0 point from a baseline expanded disability status scale score (EDSS) when the baseline score is less than or equal to 5.5; or
(b) increasing at least 0.5 points when the baseline EDSS score is greater than 5.5.

### Claim 71 (depends on 68, 69, 70)

The method of any one of claims 68-70, wherein the patient with PPMS has:
(a) a PPMS diagnosis with an expanded disability status scale score (EDSS) between 2.0 and 6.5; and
(b) a cerebrospinal fluid (CSF) analysis that is positive for isoelectric focusing evidence of oligoclonal bands or elevated IgG index.

### Claim 72 (depends on 68, 69, 70, 71)

The method of any one of claims 68-71, wherein the risk reduction is relative to placebo.

### Claim 73

A method of improving time to onset of confirmed disability progression (CDP) or composite confirmed disability progression (cCDP) in a patient with primary progressive multiple sclerosis (PPMS) in need thereof, comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof, wherein the cCDP comprises progression in at least one of:
(a) CDP;
(b) sustained 20% increase in the timed 25-foot walk (T25-FW) test; and
(c) sustained 20% increase in the 9-hole peg test (9-HPT).

### Claim 74 (depends on 73)

The method of claim 73, wherein the CDP or cCDP is measured over at least three months, such as at least six months.

### Claim 75 (depends on 73, 74)

The method of claim 73 or 74, wherein the CDP comprises:
(a) increasing at least 1.0 point from a baseline expanded disability status scale score (EDSS) when the baseline score is less than or equal to 5.5; or
(b) increasing at least 0.5 points when the baseline EDSS score is greater than 5.5.

### Claim 76 (depends on 23, 24, 25)

The method of any one of claims 23-25, wherein the patient with PPMS has:
(a) a PPMS diagnosis with an expanded disability status scale score (EDSS) between 2.0 and 6.5; and
(b) a cerebrospinal fluid (CSF) analysis that is positive for isoelectric focusing evidence of oligoclonal bands or elevated IgG index.

### Claim 77 (depends on 63, 64, 65, 66, 67)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with primary progressive multiple sclerosis (PPMS) in the method of any one of claims 63-67.

### Claim 78 (depends on 68, 69, 70, 71, 72)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with primary progressive multiple sclerosis (PPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof reduces the risk of confirmed disability progression (CDP) or composite confirmed disability progression (cCDP) in the method of any one of claims 68-72.

### Claim 79 (depends on 73, 74, 75, 76)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating a patient with primary progressive multiple sclerosis (PPMS), wherein tolebrutinib or a pharmaceutically acceptable salt thereof improves time to onset of confirmed disability progression (CDP) or composite confirmed disability progression (cCDP) in the method of any one of claims 73-76.

### Claim 80

A method of treating disability accumulation in a patient with multiple sclerosis comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 81

A method of treating disability progression independent of relapse activity in a patient with multiple sclerosis comprising administering to the patient in need thereof a therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof.

### Claim 82 (depends on 80, 81)

The method of claim 80 or 81, wherein treating disability accumulation or disability progression independent of relapse activity comprises at least one of:
(a) reducing the risk of disability accumulation in the patient in need thereof,
(b) delaying disability accumulation in the patient in need thereof; or
(c) improving time to onset of disability accumulation in the patient in need thereof.

### Claim 83 (depends on 80, 81, 82)

The method of any one of claims 80-82, wherein the disability accumulation or disability progression independent of relapse activity is confirmed disability accumulation (CDA).

### Claim 84 (depends on 83)

The method of claim 83, wherein the confirmed disability accumulation (CDA) is confirmed disability progression (CDP).

### Claim 85 (depends on 83)

The method of claim 83, wherein the confirmed disability accumulation (CDA) is confirmed disability worsening (CDW).

### Claim 86 (depends on 83)

The method of claim 83, wherein the confirmed disability accumulation (CDA) is a composite confirmed disability accumulation (cCDA) comprising progression in one or more of:
(a) CDW or CDP;
(b) sustained 20% increase in the timed 25-foot walk test (T25-FW); and
(c) sustained 20% increase in the 9-hole peg test (9-HPT).

### Claim 87 (depends on 84, 86)

The method of claim 84 or 86, wherein the CDP comprises:
(a) increasing at least 1.0 point from a baseline expanded disability status scale score (EDSS) when the baseline score is less than or equal to 5.0; or
(b) increasing at least 0.5 points when the baseline EDSS score is greater than 5.0.

### Claim 88 (depends on 85, 86)

The method of claim 85 or 86, wherein the CDW comprises:
(a) increasing at least 1.5 point from a baseline expanded disability status scale score (EDSS) when the baseline score is 0;
(b) increasing at least 1.0 point from the baseline EDSS when the baseline score is greater than or equal to 0.5 and less than or equal to 5.5; or
(c) increasing at least 0.5 points when the baseline EDSS score is greater than 5.5.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The method of any one of claims 83-88, wherein the CDA or cCDA is measured over at least 3 months, such as at least 6 months.

### Claim 90 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The method of any one of claims 80-90, wherein the patient in need thereof has secondary progressive multiple sclerosis (SPMS).

### Claim 91 (depends on 91)

The method of claim 91, wherein the SPMS is non-relapsing secondary progressive multiple sclerosis (nrSPMS).

### Claim 92 (depends on 91)

The method of claim 91, wherein the SPMS is relapsing secondary progressive multiple sclerosis (R-SPMS).

### Claim 93 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 80-89, wherein the patient in need thereof has a relapsing form of multiple sclerosis (RMS).

### Claim 94 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 80-89, wherein the patient in need thereof has primary progressive multiple sclerosis (PPMS).

### Claim 95 (depends on 80, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating disability accumulation in a patient with multiple sclerosis in the method of any one of claims 80 or 82-94.

### Claim 96 (depends on 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

Tolebrutinib or a pharmaceutically acceptable salt thereof for use in treating disability progression independent of relapse activity in a patient with multiple sclerosis in the method of any one of claims 81-94.

### Claim 97 (depends on 1, 2, 3, 4, 5, 38)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-5 or 38, wherein one or more of the reduction in risk of CDP, reduction in total number of new and/or enlarging T2-hyperintense lesions, reduction in risk of sustained 20% increase in T25-FW test, or the improvement of chance of CDI is relative to placebo.

### Claim 98 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 44, 45, 46, 47)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 26-37 or 44-47, wherein the time to onset is improved relative to placebo.

### Claim 99 (depends on 53, 54, 55, 56, 61)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 53-56 or 61, wherein the time to onset is improved relative to treatment with teriflunomide.

### Claim 100 (depends on 63, 64, 65, 66, 67, 77, 78)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 63-67 or 77-78, wherein one or more of the reduction in risk of CDP or cCDP, the reduction in total number of new and/or enlarging T2-hyperintense lesions, the reduction in risk of sustained 20% increase in T25-FW test, the reduction in risk of sustained 20% increase in the 9-hole peg test (9-HPT), the improvement of chance of CDI, or the improvement percent change in BVL is relative to placebo.

### Claim 101 (depends on 73, 74, 75, 76, 79)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 73-76 or 79, wherein the time to onset is improved relative to placebo.

### Claim 102 (depends on 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 82-96, wherein one or more of the reduction of risk, delay, or improvement of time to onset of disability accumulation is relative to placebo.

### Claim 103 (depends on 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 82-96, wherein one or more of the reduction of risk, delay, or improvement of time to onset of disability accumulation is relative to treatment with teriflunomide.

### Claim 104 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-47, 80-98, or 102, wherein the patient in need thereof has one or more Gd-enhancing T1-hyperintense lesions as detected by MRI before administration of tolebrutinib.

### Claim 105 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-47, 80-98, or 102, wherein the patient in need thereof:
(a) has no Gd-enhancing T1-hyperintense lesions as detected by MRI before administration of tolebrutinib; and
(b) had no relapse in the 2 years before administration of tolebrutinib.

### Claim 106 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-47, 80-98, or 102, wherein the patient in need thereof has an EDSS score of 4.5 or less before administration of tolebrutinib.

### Claim 107 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-47, 80-98, or 102, wherein the patient in need thereof has an EDSS score of 5.5 or less before administration of tolebrutinib.

### Claim 108 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-47, 80-98, or 102, wherein the patient in need thereof has received 1 or fewer disease modifying therapies for multiple sclerosis before administration of tolebrutinib.

### Claim 109 (depends on 108)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of claim 108, wherein the patient in need thereof has not received a disease modifying therapy before administration of tolebrutinib.

### Claim 110 (depends on 108)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of claim 108, wherein the patient in need thereof has received one prior disease modifying therapy selected from the group consisting of an interferon, glatiramer acetate, dimethyl fumarate, ocrelizumab, teriflunomide, natalizumab, fingolimod, and rituximab.

### Claim 111 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-47, 80-98, or 102, wherein the patient in need thereof had onset of RMS symptoms 10 years or less before administration of tolebrutinib, such as 5 years or less before administration of tolebrutinib or more than 5 and 10 years or less before administration of tolebrutinib.

### Claim 112 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 99)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 48-62, 80-96, 99, or 103, wherein the patient in need thereof has an EDSS score of less than 4 before administration of tolebrutinib.

### Claim 113 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 99)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 48-62, 80-96, 99, or 103, wherein the patient in need thereof has one or more Gd-enhancing T1-hyperintense lesions as detected by MRI before administration of tolebrutinib.

### Claim 114 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 99)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 48-62, 80-96, 99, or 103, wherein the patient in need thereof has not received a disease modifying therapy multiple sclerosis before administration of tolebrutinib.

### Claim 115 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 99)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 48-62, 80-96, 99, or 103, wherein the patient in need thereof had onset of RMS symptoms less than 10 years before administration of tolebrutinib, such as less than 5 years before administration of tolebrutinib or 5 or more and less than 10 years before administration of tolebrutinib.

### Claim 116 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 99)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 48-62, 80-96, 99, or 103, wherein the patient in need thereof had 2 or more relapses in the one year before administration of tolebrutinib.

### Claim 117 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-62 or 80-99, or 102-103, wherein the patient in need thereof has one or more phase rim lesion (PRL) as detected by MRI before administration of tolebrutinib.

### Claim 118 (depends on 117)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of claim 117, wherein the patient in need thereof has one, two, or three phase rim lesions (PRL) as detected by MRI before administration of tolebrutinib.

### Claim 119 (depends on 117)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of claim 117, wherein the patient in need thereof has four or more phase rim lesions (PRL) as detected by MRI before administration of tolebrutinib.

### Claim 120 (depends on 1, 119)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-119, wherein the patient in need thereof is an adult with multiple sclerosis.

### Claim 121 (depends on 1, 120)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-120, wherein the therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof is about 5 mg to about 60 mg, measured in base form.

### Claim 122 (depends on 1, 120)

The method, or tolebrutinib or pharmaceutically acceptable salt thereof for use, of any one of claims 1-120, wherein the therapeutically effective amount of tolebrutinib or pharmaceutically acceptable salt thereof is 60 mg, measured in base form.
